Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer

This is a multi-center single arm phase II study of zanzalintinib after Pluvicto in chemotherapy-naïve mCRPC. Subjects will receive zanzalintinib 60mg orally (PO) once daily. Zanzalintinib may continue until evidence of radiographic progression, intolerable adverse events, or withdrawal of consent. Two interim analyses will be performed; a safety interim analysis to be performed for the first 5 evaluable subjects, and a futility interim analysis to be performed for the first 15 evaluable subjects.

NCT Number	NCT07623460
Lead Sponsor	Stuthi Perimbeti Collaborators: Exelixis, Penn State Cancer Institute
Conditions	mCRPC (Metastatic Castration-resistant Prostate Cancer)
Enrollment	30 participants
Start Date	2026-09
Primary Completion	2028-09 (estimated)
Study Completion	2031-09 (estimated)
Updated on ClinicalTrials.gov	2026-06-03